MNK's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.07 -- higher than just 2.04% of US-listed equities with positive expected earnings growth.
Price to trailing twelve month operating cash flow for MNK is currently 0.13, higher than just 1.85% of US stocks with positive operating cash flow.
With a price/sales ratio of 0.03, Mallinckrodt plc has a higher such ratio than just 0.86% of stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Mallinckrodt plc are OSMT, ACOR, IAG, AA, and FTI.
Mallinckrodt plc Ordinary Shares (MNK) Company Bio
Mallinckrodt Public Limited Company is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology, neonatal critical care respiratory therapies, and analgesics and central nervous system drugs. The company was founded in 2013 and is based in Dublin, Ireland.
A bird in the hand is worth two in the bush. - J. Capgrave "WSJ is controlled by shorties", "This is another trick to trick retail investors to give up their shares" and "#FakeNews". The recent WSJ article has incited vehement comments among stolid Mallinckrodt (MNK) investors, mostly criticizing and...
Zheng Feng Chee on Seeking Alpha | October 2, 2020
BETHLEHEM, Pa., Oct. 2, 2020 /PRNewswire/ -- B. Braun Medical Inc. announces that it has previously settled a patent infringement litigation brought by Mallinckrodt Hospital Products Inc., its affiliates, and New Pharmatop L.P. in response to B. Braun's new drug application (NDA) seeking…
Los Angeles, United State, – – QY Research recently added a research report, Global Nuclear Medicine/Radiopharmaceutic Market Research Report 2020 to its ever-increasing repository. The research report discusses the future of the global Nuclear Medicine/Radiopharmaceutic market. It highlights the drivers
September proved to be a mixed month as far as drug approvals are concerned, with Mallinckrodt PLC (NYSE: MNK ) and Aquestive Therapeutics Inc (NASDAQ: AQST ) facing rejections. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Among the more fortunate ones were GlaxoSmithKline plc (NYSE: GSK ), which got the nod for an expanded indication - hypereosinophilic syndrome. Bristol-Myers Squibb Co's (NYSE: BMY ) leukemia drug also received FDA's blessings, and after several hiccups, Eton Pharmaceuticals Inc's (NASDAQ: ETON ) out-licensed preservative-free allergic conjunctivitis ophthalmic...